Rising Pharmaceuticals Bolsters U.S. Supply Chain by Expanding Sterile Dosage Capabilities, Including Injectables and Ophthalmics, with Opening of New Facility
- IN Press Releases
- Source
Optimizes supply chain security by strategically locating manufacturing site in Decatur, Illinois
EAST BRUNSWICK, N.J.–(BUSINESS WIRE)–Rising Pharma Holdings Inc., dba as Rising Pharmaceuticals, today announced the opening of a commercial manufacturing facility in Decatur, Illinois, to manufacture and package sterile products, including injectables and ophthalmic products in response to critical pharmaceutical supply shortages in the U.S. The site comprises a manufacturing and packaging facility spanning a combined 230,000 square feet. The move is expected to augment Rising’s existing product portfolio and offer a wider basket of products for customers.
“Rising Pharmaceuticals is proud to play a significant role supporting the healthcare system by producing more than 180 commercialized generic medicines and over 620 active SKU on the market. With one of the broadest portfolios of any U.S. generic pharmaceuticals company, we recognize that expanding manufacturing capabilities in the U.S. is mission-critical for our continued commercial success, as well as for public health in general,” said Vimal Kavuru, CEO of Rising Pharmaceuticals. “The new facility will adhere to stringent quality standards to produce generic medications that are effective and cost-efficient.”
“We look forward to creating a model of sustainable development through our partnership with the Decatur community, balancing efficient U.S. manufacturing growth while competing in the global pharmaceutical supply chain,” said Steven Coventry, Vice President of Operations and General Manager, Rising Pharmaceuticals. “Our facility is reemerging from a prior closure and has been a staple of the Decatur community since 1952. We anticipate that the new site will help create jobs, economic growth, and enhance healthcare accessibility.”
About Rising Pharmaceuticals
Rising Pharmaceuticals, a portfolio company of H.I.G. Capital, is a leading provider of generic and specialty-branded pharmaceuticals in the U.S. Rising focuses on the development, regulatory, and commercial aspects of the product life cycle while outsourcing certain manufacturing to its network of strategic CMO and CDO partners. The Company is based in New Brunswick, New Jersey, and is expanding its manufacturing footprint with a new facility in Decatur, Illinois. For more information about the Company, please visit www.risingpharma.com.
For Media Inquiries:
Marina Wissa, (201) 961 9013
mediainquiries@risingpharma.com
Glenn Silver, (646) 871-8485
Glenn.Silver@finnpartners.com
For Customer Service Inquiries:
Jason Eisner, (201) 961 9000
customerservice@risingpharma.com
Nand Desai is dedicated to driving strategic transformations and integrations within the organization, leveraging his extensive experience across all functional groups to ensure successful execution. He holds a BBA from the University of Michigan – Ross School of Business. Before joining Rising, Nand was engaged in private equity at H.I.G. Capital, where he focused on middle-market opportunities. He began his career as an Analyst in the M&A group at Greenhill & Co., gaining valuable experience in financial analysis and advisory services.
Nand Desai is dedicated to driving strategic transformations and integrations within the organization, leveraging his extensive experience across all functional groups to ensure successful execution. He holds a BBA from the University of Michigan – Ross School of Business. Before joining Rising, Nand was engaged in private equity at H.I.G. Capital, where he focused on middle-market opportunities. He began his career as an Analyst in the M&A group at Greenhill & Co., gaining valuable experience in financial analysis and advisory services.